Skip directly to site content Skip directly to search


Español  Other Languages


Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People
 Search

		Submit


Tick-borne encephalitis (TBE)








Clinical Evaluation and Disease										Related Pages
										Tick-borne encephalitis (TBE) virus is an RNA virus in the genus *Flavivirus* (family *Flaviviridae*). It was discovered in the former Soviet Union in 1937. The three main subtypes are the European, Far Eastern, and Siberian subtypes. TBE virus is closely related to Powassan virus, a domestic arbovirus also transmitted by ticks.
Clinical Signs and Symptoms
Most human infections with TBE virus are asymptomatic. For those who become ill, the incubation period is usually between 7 and 14 days (range:  4–28 days). Acute neuroinvasive disease (i.e., aseptic meningitis, encephalitis, or meningoencephalomyelitis) is the most commonly recognized clinical manifestation of TBE virus infection. Milder forms of the disease (e.g., febrile illness) also occur.
TBE disease can present as a biphasic illness, particularly with the European subtype of the virus, as follows:
First phase: a nonspecific febrile illness that might be accompanied by symptoms such as headache, malaise, myalgia, anorexia, nausea, and/or vomiting. This phase usually lasts for several days and is followed by an afebrile and relatively asymptomatic period, typically of about one week’s duration.
Second phase: a clinical illness with central nervous system involvement. Depending on specific presentation, findings can include meningeal signs, altered mental status, cognitive dysfunction, ataxia, rigidity, seizures, tremors, cranial nerve palsies, and limb paresis.Infections with the Far Eastern TBE virus subtype are generally more severe than infections with the other two subtypes. Children typically have a milder illness than adults, more frequently presenting with meningitis. Disease severity is highest in older persons.
Differential Diagnosis
The differential diagnoses will vary depending on the travel and exposure history of the patient, remembering that for some travelers, infection could have been acquired locally before or after travel. For patients presenting with neurologic disease, the differential diagnosis might include a wide range of infectious and non-infectious etiologies. Other arboviruses transmitted in some areas where TBE occurs include West Nile, Usutu, and Japanese encephalitis viruses. In patients with known exposure to ticks, other tickborne diseases might be considered, including Lyme borreliosis.
Outcomes
The case fatality rate and frequency of neurologic sequelae vary by viral subtype. With the European subtype, the case fatality rate is about 1–2%, with the Siberian subtype about 6–8%, and with the Far Eastern subtype, the case fatality rate is about 20%. Sequelae rates ranging from 10–50% have been reported from different areas. Chronic and progressive forms of disease have been reported, particularly after infection with the Siberian subtype.
							
					
							Last Reviewed:  January 26, 2023						Source: 	Centers for Disease Control and Prevention, National Center for Emerging and Zoonotic Infectious Diseases (NCEZID), Division of Vector-Borne Diseases (DVBD)
					Facebook
        Twitter
        LinkedIn
        Syndicate homeTick-borne encephalitis (TBE) Home
Prevention
Transmission
Geographic Distribution
For Healthcare Providersplus icon
Clinical Evaluation & Disease
Diagnostic Testing
Treatment & Prevention
Vaccine
Symptoms, Diagnosis, & Treatment
Vaccine
Links & References


About CDC
					Contact Us
					800-232-4636
 Facebook Twitter Instagram LinkedIn Youtube Pinterest Snapchat
 CONTACT CDC
				Contact Us
							Call 800-232-4636
							Email Us
			ABOUT CDC
				About CDC
							Jobs
							Funding
			POLICIES
				Accessibility
							External Links
							Privacy
							Policies
							No Fear Act
							FOIA
							OIG
							Nondiscrimination
							Vulnerability Disclosure Policy
			CONNECT WITH US
				Facebook
								Twitter
								Instagram
								LinkedIn
							Youtube
								Pinterest
								Snapchat
								Email
			LANGUAGES
				Español
							繁體中文
							Tiếng Việt
							한국어
							Tagalog
							Русский
							العربية
							Kreyòl Ayisyen
							Français
							Polski
							Português
							Italiano
							Deutsch
							日本語
							فارسی
							English


U.S. Department of Health & Human Services
			Accessibility
			External Links
			Privacy
			Policies
			No Fear Act
			FOIA
			Nondiscrimination
			OIG
			Vulnerability Disclosure Policy
			USA.gov


Exit Notification / Disclaimer Policy Close
 Links with this icon  indicate that you are leaving the CDC website. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
				Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
				You will be subject to the destination website's privacy policy when you follow the link.
				CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. Website Disclaimers
 Cancel Continue